S&P Futures
5,970.00 +11.75 (+0.20%) Dow Futures
43,969.00 +68.00 (+0.15%) Nasdaq Futures
20,960.75 +66.75 (+0.32%) Russell 2000 Futures
2,417.10 +11.30 (+0.47%) Crude Oil
70.90 -0.79 (-1.10%) Gold
2,677.90 +1.60 (+0.06%)
| Previous Close | 1.2800 |
| Open | 1.2300 |
| Bid | 1.1800 x 40000 |
| Ask | 1.2100 x 40000 |
| Day's Range | 1.1900 - 1.2600 |
| 52 Week Range | 1.0300 - 10.8000 |
| Volume | |
| Avg. Volume | 38,210 |
| Market Cap | 5.725M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.0000 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireOrgenesis Commences Trading on OTCQX® Best Market
Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following i
- GlobeNewswire
Orgenesis Announces Reverse Stock Split
GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company’s common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company’s existing trading
